[{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Alprostadil","moa":"Prostanoid EP1 receptor | Prostanoid EP2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"UCB Pharma S.A \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Advanz Pharma"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Alprostadil","moa":"Prostanoid EP1 receptor | Prostanoid EP2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"UCB Pharma S.A \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Advanz Pharma"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bepranemab","moa":"Microtubule-associated protein tau","graph1":"Neurology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bepranemab","moa":"Microtubule-associated protein tau","graph1":"Neurology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Immunology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UCB Pharma S.A \/ Syndax Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Syndax Pharmaceuticals"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Zampilimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ginisortamab","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Tipiracil HCl","moa":"||Gremlin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"7","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"UCB1381","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"UCB4594","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"7","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Zampilimab","moa":"monoclonal antibodies: immunomodulating","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"UCB7853","moa":"Synuclein alpha (SNCA)","graph1":"Neurology","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bepranemab","moa":"Microtubule-associated protein tau","graph1":"Neurology","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"CBC Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Divestment","leadProduct":"Levetiracetam","moa":"Voltage-gated N-type calcium channel alpha-1B subunit | Synaptic vesicle glycoprotein 2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0.68000000000000005,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.68000000000000005,"dosageForm":"Oral Syrup","sponsorNew":"UCB Pharma S.A \/ CBC Group","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ CBC Group"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"Synaptic vesicle glycoprotein 2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"Synaptic vesicle glycoprotein 2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"Synaptic vesicle glycoprotein 2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"Synaptic vesicle glycoprotein 2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"Synaptic vesicle glycoprotein 2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Nippon Shinyaku","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Zogenix","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Nippon Shinyaku","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Nippon Shinyaku"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Zogenix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":1.8999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":1.8999999999999999,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Zogenix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0.22,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.22,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Undisclosed"},{"orgOrder":0,"company":"Zogenix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.20000000000000001,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Zogenix","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":1.8999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":1.8999999999999999,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Moksha8 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Piracetam","moa":"nootropes (piracetam type)","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fenfluramine","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"11","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"Synaptic vesicle glycoprotein 2A","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"Synaptic vesicle glycoprotein 2A","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"Synaptic vesicle glycoprotein 2A","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"Synaptic vesicle glycoprotein 2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Alprazolam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Alprazolam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Engage Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Acquisition","leadProduct":"Alprazolam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0.27000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.27000000000000002,"dosageForm":"Oral Inhalation","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Zogenix","sponsor":"Zogenix","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenfluramine","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Zogenix","highestDevelopmentStatusID":"10","companyTruncated":"Zogenix \/ Zogenix"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fenfluramine","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Padsevonil","moa":"GABA-A receptor; anion channel | Synaptic vesicle protein","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Parkinson Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"UCB0599","moa":"Alpha-synuclein misfolding","graph1":"Neurology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"UCB Pharma S.A \/ Parkinson Study Group","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Parkinson Study Group"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"UCB0022","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Minzasolmin","moa":"SNCA","graph1":"Neurology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Doxecitine","moa":"TK2","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Neuropore Therapies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Minzasolmin","moa":"SNCA","graph1":"Neurology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0.46000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.46000000000000002,"dosageForm":"Oral Capsule","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Minzasolmin","moa":"SNCA","graph1":"Neurology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"UCB Pharma S.A \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Alprazolam","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Alprazolam","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"UCB0599","moa":"Alpha-synuclein misfolding","graph1":"Neurology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"UCB0022","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"Synaptic vesicle glycoprotein 2A","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"Synaptic vesicle glycoprotein 2A","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"Synaptic vesicle glycoprotein 2A","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Alprazolam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Padsevonil","moa":"GABA-A receptor; anion channel | Synaptic vesicle protein","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"UCB0599","moa":"Alpha-synuclein misfolding","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Handl therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"4","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"ClearPoint Neuro","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"3","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Aitia","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"2","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Pheno Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"UCB Pharma S.A \/ Pheno Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"UCB Pharma S.A \/ Pheno Therapeutics"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Ariceum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"2","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Lacerta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"2","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Doxecitine","moa":"TK2","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Romosozumab","moa":"Sclerostin","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Amgen Inc"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Ra Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":2.2999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":2.2999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Ra Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Ra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ Ra Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Ra Pharmaceuticals \/ Ra Pharmaceuticals"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase IV","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Donzakimig","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Neurology","graph2":"IND Enabling","graph3":"Ra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Romosozumab","moa":"Sclerostin","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Highmark","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Zogenix","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenfluramine","moa":"Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zogenix \/ Zogenix","highestDevelopmentStatusID":"11","companyTruncated":"Zogenix \/ Zogenix"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dapirolizumab Pegol","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dapirolizumab Pegol","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dapirolizumab Pegol","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dapirolizumab Pegol","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Biogen"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Romosozumab","moa":"Sclerostin","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MT1621","moa":"Thymidine kinase 2","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"UCB9741","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BELGIUM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Alprazolam","moa":"GABA-A receptor; anion channel","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Minzasolmin","moa":"SNCA","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Glovadalen","moa":"D1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"UCB8600","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"UCB9741","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"UCB3101","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"IMIDomics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Financing","leadProduct":"IMB1001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"4","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Praxis Precision Medicines","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"PRAX-020","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"UCB Pharma S.A","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"4","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Zogenix","sponsor":"Tevard Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Zogenix","amount2":0.12,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Zogenix \/ Zogenix","highestDevelopmentStatusID":"3","companyTruncated":"Zogenix \/ Zogenix"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Ailux Biologics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ UCB Pharma S.A","highestDevelopmentStatusID":"3","companyTruncated":"UCB Pharma S.A \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Neurology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by UCB Pharma S.A

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 14, 2025

                          Lead Product(s) : Glovadalen

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 31, 2024

                          Lead Product(s) : Doxecitine

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase II

                          Recipient : Cristina Domínguez González

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          December 06, 2024

                          Lead Product(s) : Rozanolixizumab

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Bimzelx (bimekizumab) is a humanized IgG1 mAbs that selectively binds to IL-17A, IL-17F and IL-17AF cytokines. It is indicated in adults with moderate-to-severe hidradenitis suppurativa.

                          Product Name : Bimzelx

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          November 20, 2024

                          Lead Product(s) : Bimekizumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          September 27, 2024

                          Lead Product(s) : Dapirolizumab Pegol

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : CDP7657 (dapirolizumab pegol), a novel Fc-free anti-CD40L drug candidate, investigated in people living with moderate-to-severe systemic lupus erythematosus (SLE).

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          September 24, 2024

                          Lead Product(s) : Dapirolizumab Pegol

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Biogen

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Bimzelx (bimekizumab) is an antibody that selectively binds to IL-17A, IL-17F and IL-17AF cytokines. It is indicated for psoriatic arthritis & non-radiographic axial spondyloarthritis.

                          Product Name : Bimzelx

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          September 23, 2024

                          Lead Product(s) : Bimekizumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 19, 2024

                          Lead Product(s) : Doxecitine

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Rystiggo (rozanolixizumab) is a humanized IgG4 monoclonal antibody that binds to the FcRn resulting in the reduction of circulating IgG. It is approved by EMA for generalized myasthenia gravis.

                          Product Name : Rystiggo

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          August 01, 2024

                          Lead Product(s) : Rozanolixizumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 01, 2024

                          Lead Product(s) : Minzasolmin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank